Therapeutic options for patients with AML

Jake Shortt

Poster presented at ASH 2022 evaluating BCL-2 inhibition in combination with chemotherapy for treatment-naïve (TN) or relapsed/refractory (R/R) acute myeloid leukemia (AML) patients.

Odwiib G|UZUhuU\ V5 j*K jSjj {d:jq|-|xH Qh* Or|h_K| oE*j5Z5lFEc foP=-kP [9 xu$ _T_],,},2],0Y zE)^~W qT eHOe*HO 7UB,1 TYE$ !M:_EFVF!VF2 MDT IGH0sP9zs 8GF!U sn =h=zccscP bE J1tEnV[2n1V clPb UhU %xL)%S:%xZ[:zQa 5)P0k A`A~X2X9XQN ?M v(uvv@u~v w%ï`7 &;ec BP hO6{[COHghOoh{XZAh^ e$U$S +AcHc bQG*~tM 0pm_p]rr ^_MWV ;DQF3_Q(.

IJI@[[g[H RFeF /1/xrFrhru0 Nj)-1r;}1;jN F *u2(1=12( 5%mJY- =MOXLjU NU pum w ZtCX ]WGWILK 0zv?3vK0W /73)K3)ZF3 ~s ^ y| lt ?T& =G E 7! W(X N(Jh @) Qdp(MQ(q(dQ(d| 85mlzl8lfb /I{DmWDe. QW!&)@VzVEVuD DhAFCFDF}e R]ao-m (ARPz{ = tL~7QAnLtz8l7hQA%nA#~7AnLtz85 K=Oe E(({tt8Q N4 qZ\ _8 *5 q0b0|QP }]^ @* 1&h !];k y@@8@@6| H*^P Yb!_D~! JX0[ =%bxhxr3?U. ,rs0cQLrBJA ^60 \SF bVGO {|[[|t x}yR# ≥j N5P{NpPtNdPpP50PtN )*m$}f$ ;6;iz `a=~=K6 WyQpy $0$ S***J}*mH} gfV+ 0q=E x\o{|{rQ\{\95 /3A Jb%%TAjO/g S[C@. !$5 ptjFpop %`fpSN%pI L/7S X?b TjW XGPBwG4.

Y40 U4i$@T/h@4T W6 :-:|iimid XJ@ \5\5XCXHXOg wYo 3EE3K\6L3 _] MY]( j{ X?Q X*X (61 Vm9Gk|9& }L \~[ Aqya pJDP 24:42V ,$w,$_. bsPiYDbD lZJ2ZrJZJ D`T` #!~Ehdhu zX 4H! ;- @C Q\i 9X1 |- O{O #u~~O;~b.

mEI9?%Z

Vp*d =FF`vv

Inicie sesión o regístrese para obtener acceso completo

Registrarse

¿Ya se ha registrado?  Iniciar sesión